Stock Events

Stock Events

Addex Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APE.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes plc operates in the CNS therapeutic area, making it a direct competitor to Addex Therapeutics in developing treatments for neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
ACADIA Pharmaceuticals specializes in CNS disorders, including Parkinson’s disease psychosis, directly competing with Addex's focus areas.
BridgeBio Pharma
BBIO
Mkt Cap14.18B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, overlapping with Addex Therapeutics' research focus.
Biogen
BIIB
Mkt Cap26.03B
Biogen is a major player in neurodegenerative diseases, Alzheimer's, and multiple sclerosis, competing in the CNS space.
AMGEN
AMGN
Mkt Cap187.56B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neurological space.
Palatin Technologies
PTN
Mkt Cap31.4M
Palatin Technologies works on developing therapeutics for diseases with a focus on CNS, making it a competitor in the neurological treatment market.
Novartis
NVS
Mkt Cap297.32B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Addex in the broader CNS therapeutic area.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a wide range of therapeutic areas, including CNS disorders, making it a competitor in developing treatments for neurological conditions.

About

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Show more...
CEO
Mr. Timothy Mark Dyer
Employees
27
Country
United Kingdom
ISIN
CH0029850754

Listings

STU
DE
APE1.STU
MU
DE
APE.MU
LSE
GB
0QNV.LSE
STU
DE
APE.STU

0 Comments

Share your thoughts

FAQ

What is Addex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Addex Therapeutics stocks are traded under the ticker APE.MU.
How many employees does Addex Therapeutics have?▼
As of April 11, 2026, the company has 27 employees.
In which sector is Addex Therapeutics located?▼
Addex Therapeutics operates in the Energy sector.
When did Addex Therapeutics complete a stock split?▼
Addex Therapeutics has not had any recent stock splits.
Where is Addex Therapeutics headquartered?▼
Addex Therapeutics is headquartered in Geneva, United Kingdom.